Accelerate Diagnostics, Inc. (AXDXQ)

Market Cap	25.00
Revenue (ttm)	11.70M -3.0%
Net Income	-50.05M
EPS	-2.15
Shares Out	25.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,246
Open	0.000001
Previous Close	0.000001
Day's Range	0.000001 - 0.000001
52-Week Range	n/a
Beta	-0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 18, 2025

About Accelerate Diagnostics

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides Accelerate PhenoTest BC Kit, a test kit for the system, which is indicated as an aid, in conjuncti...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1982
• Employees: 107
• Stock Exchange: OTCMKTS
• Ticker Symbol: AXDXQ

Financial Performance

In 2024, Accelerate Diagnostics's revenue was $11.70 million, a decrease of -2.99% compared to the previous year's $12.06 million. Losses were -$50.05 million, -18.78% less than in 2023.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 22, 2025

Data Sources Report a data error